Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Product type

Thumbnail
June 27, 2019

Bracco’s Blue Earth buy boosts Syncona

Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.

Thumbnail
July 30, 2018

Having set the stage, Boston plans its performance

Which groups might Boston Scientific bolt on next?

Article image
Vantage logo
July 25, 2018

Congenica aims to turn data into information

Sequencing data is all well and good, but what does it mean?

Article image
Vantage logo
July 23, 2018

Bayer’s second-to-last medtech stream dries up

Bayer's only remaining medical technology franchise is its radiology business.

Article image
Vantage logo
July 18, 2018

Despite the FDA’s best efforts, device approvals crash

Regulatory intervention having limited impact on fostering innovation.

Article image
Vantage logo
July 17, 2018

Floating device companies stay at home

Nine IPOs have got away so far this year, and one of them is very big indeed.

Article image
Vantage logo
July 11, 2018

Five-year low for medical device mergers

A return to tuck-in deals – sort of.

Article image
Vantage logo
July 11, 2018

$100m venture rounds become standard for device makers

The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.

Article image
Vantage logo
July 05, 2018

Fireworks among the small and mid-cap device makers

Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.

Article image
Vantage logo
July 04, 2018

So far so adequate for big-cap medtech

Big cap medtech disappoints – but still beats pharma.

Article image
Vantage logo
June 26, 2018

GE finally spins out Healthcare

GE arrives to the spin-out party fashionably late.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.